Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler

Headache
S B ShrewsburyN Ramadan

Abstract

We investigated the pulmonary absorption of dihydroergotamine (DHE) mesylate and compared the safety, pharmacokinetic, and metabolic profile of 4 different doses of orally inhaled DHE delivered by the Tempo Inhaler (MAP Pharmaceuticals Inc., Mountain View, CA, USA) with 1.0 mg intravenously (IV) administered DHE in 18 healthy subjects. Safety was measured by monitoring adverse events, vital signs, electrocardiograms, spirometry, and changes in biochemical and hematological laboratory values. Liquid chromatography, tandem mass spectrometry was used to determine plasma DHE levels while C(max), t(max), AUC(0-6), AUC(0-48), AUC(0-inf), and t(1/2) of parent DHE and the major bioactive metabolite, 8'OH-DHE. Pharmacokinetic parameters and qualitative spectrograms for DHE and metabolites for all treatment groups were compared after inhaled DHE (MAP0004) and IV DHE 1.0 mg. Geometric means and 90% confidence intervals of log-transformed data were calculated and the ratio of means compared. Inhaled DHE resulted in rapid systemic absorption with pharmacokinetic parameters of both parent DHE and 8'OH-DHE similar to those achieved after a 3-minute IV infusion. Post-peak (t(max) approximately 12 minutes) DHE concentrations achieved after 4 ac...Continue Reading

References

Jan 1, 1991·European Journal of Clinical Pharmacology·P A WyssW H Aellig
Jan 25, 2002·The New England Journal of Medicine·Peter J GoadsbyMichel D Ferrari
Apr 19, 2005·Headache·Richard B Lipton, Marcelo E Bigal
May 17, 2006·Current Opinion in Neurology·Lars Jacob Stovner, Knut Hagen
Nov 3, 2006·Headache·Joel R Saper, Stephen Silberstein
Nov 3, 2006·Headache·Joel R SaperAlan Rapoport

❮ Previous
Next ❯

Citations

Sep 4, 2009·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A Rapoport
May 22, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Alan M Rapoport
May 6, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A Rapoport
Jun 1, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Alan M Rapoport
May 25, 2013·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Abraham J Nagy, Alan M Rapoport
Jan 29, 2011·Current Pain and Headache Reports·Giorgio Lambru, Manjit Matharu
Apr 27, 2013·CNS Drugs·Stephen D Silberstein, Shashidhar H Kori
May 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stephen D Silberstein
Jan 1, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Donald J KellermanShashidhar Kori
Jul 25, 2012·CNS Drugs·Arnaldo N Da Silva, Stewart J Tepper
Nov 3, 2012·Drugs·Ryan J CadyRoger K Cady
Jul 11, 2013·CNS Drugs·Sarah Vollbracht, Alan M Rapoport
Jul 27, 2012·Therapeutic Delivery·Peter NoymerJames Cassella
May 29, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Sarah Vollbracht, Alan M Rapoport
Aug 7, 2012·Expert Opinion on Pharmacotherapy·Stephen Silberstein
Jun 10, 2011·Expert Review of Neurotherapeutics·Michail Vikelis, Alan M Rapoport
Jul 25, 2009·Expert Opinion on Drug Metabolism & Toxicology·Markus Schürks
Apr 23, 2013·Revue neurologique·M Lanteri-Minet
Apr 5, 2011·Trends in Pharmacological Sciences·Jes Olesen, Messoud Ashina
Oct 2, 2009·The Journal of Headache and Pain·Lars Jacob StovnerKnut Hagen
Sep 18, 2013·Headache·Stewart J Tepper
Apr 1, 2010·Headache·Eric P Baron, Stewart J Tepper
May 12, 2010·Headache·Todd J Schwedt, Stephen D Silberstein
Jul 15, 2016·Expert Opinion on Pharmacotherapy·Abigail L Chua, Stephen Silberstein
Mar 18, 2011·Toxicologic Pathology·Thomas A ArmerAllen Singer
Aug 1, 2014·Cephalalgia : an International Journal of Headache·Sieneke LabruijereAntoinette MaassenVanDenBrink
Dec 17, 2011·Cephalalgia : an International Journal of Headache·D KellermanDw Dodick
Mar 30, 2019·Expert Opinion on Drug Discovery·Nicolas Vandenbussche, Peter J Goadsby
Oct 28, 2016·Nature Reviews. Neurology·Nathaniel M Schuster, Alan M Rapoport
Nov 19, 2019·Headache·Stephen D SilbersteinJohn Hoekman
May 21, 2017·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Kasra MaasumiAlan M Rapoport
Nov 18, 2010·Expert Opinion on Pharmacotherapy·John A Morren, Nestor Galvez-Jimenez
Aug 29, 2013·Expert Review of Neurotherapeutics·Peer C Tfelt-Hansen
Dec 14, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jonathan Jia Yuan Ong, Milena De Felice
Oct 14, 2016·Science Translational Medicine·Michael M LippMartin I Freed
Oct 21, 2017·Journal of Controlled Release : Official Journal of the Controlled Release Society·Cetin TasMark R Prausnitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.